AMCP dossier development that knows which sections are out of date the day new evidence lands
Payer requests answered with a cited, label-checked packet in days.
See one case, screen by screen ↓It is the work of building and keeping current a product's dossier in the AMCP Format for Formulary Submissions, which US payers' P&T committees expect from manufacturers when they ask for it. AMCP Dossier Development keeps the dossier as a binder of AMCP sections, each tied to the sources it rests on, and answers each unsolicited payer request from it.
How to choose AI solutions for life sciences →
Updated
An AMCP dossier is a living document. The sample Veltrimab dossier runs to 17 sections and 90.7 pages, and the refresh after its ulcerative colitis approval touched 14 of them for four reasons: the new indication, the VLT-302 52-week results, 5-year psoriasis data and a new list price from January 1, 2027. Which section rests on which label revision, study report, model report or pricing memo is tracked by memory and spreadsheet, so a team often finds out what is stale at the annual review — or when a payer asks.
Every unsolicited request is then answered by hand: the asks split out, the unsolicited record written, the right edition chosen, the budget impact model set up for the plan, a cover letter drafted, MLR routed — while the P&T date comes closer. An out-of-date dossier can cost a formulary position, and a packet that carries material the payer did not ask for, or an answer on an unapproved use, can create a compliance finding.
By hand: our estimate, the split the working solution's dashboard shows. With the solution: the median days per stage over the last 30 days on its sample data.
Six specialist agents keep every section current with the evidence and build each payer packet; the dossier owner decides and MLR approves.
October 7. Veltrimab, an IL-23 p19 antagonist, was approved for ulcerative colitis on September 30, and Priya Raman is taking its Approved Product Dossier from v5.2 to v6.0. That morning new data arrives, and a request from Crestline Health Plan, received the evening before, is waiting for its P&T meeting. Here is what happens, screen by screen, in the working solution.
The binder lists the 17 AMCP Format 5.0 sections of the v6.0 draft — 90.7 pages, sign-off target October 24 — each with its owner, pages, the sources it rests on and when it was last updated. Four are current and signed, three were reviewed with no change, nine are being updated, and §4.2B Cost-effectiveness analysis waits for the UC report due October 20. The binder was checked against 412 library sources at 09:14.
“Point at a source to see the sections that rest on it.”
The VLT-302 extension week-100 results arrive from Medical Affairs as a congress abstract: two pages, one table and one Kaplan–Meier figure. Priya adds it to the evidence library with one button, “Add and check the binder”. The agents read it and check every binder section that rests on it.
§1.1B Clinical benefits, §3.1B Study summaries and §3.2B Evidence tables all rest on VLT-302 and were last updated before today, so each is marked out of date. Their freshness tracks show the new source as a tick past the last update, and the library feed shows the abstract with “3 out of date”. The library now holds 413 sources.
“3 sections now rest on evidence newer than their last update.”
“Draft the 3 updates” adds the new data to each section: of patients in clinical remission at week 52, 78.4% were still in remission at week 100 (as observed, n=208). Each value carries its citation, and the three sections go to Omar Haddad for review. The references list gains one entry.
The week-100 data is labelled “as observed” — the section writer keeps to what the source says.
§2.1B Product information shows each change with its reason — UC approval or new WAC — and its source. The indications now include ulcerative colitis, the UC dosing (600 mg IV at weeks 0, 4 and 8, then 200 mg subcutaneously every 8 weeks) and the hepatotoxicity warning are added, and the WAC reads $19,240 per 100 mg syringe, $19,860 from January 1, 2027. The section is ready to sign; 7 of 17 sections are done.
“Each change shows why — click the reason to see its source.”
In §3.2B Evidence tables, every value shows where it was read — a table or a figure — and whether it was confirmed. For week-52 endoscopic improvement the abstract says 50.1%, while Figure 3 and its source data in Table S4 say 50.2% (136 of 271). The reader recommends Table S4 because it holds the patient counts; Priya decides, and the decision goes into the change log.
Limit: no value from a figure without a confirming table or sentence.
Dr. Hannah Brooks, PharmD, sent REQ-2417 through the eDossier portal on October 6 for Crestline's November 12 P&T meeting — 1.4M lives. The binder maps each ask to the sections that answer it: A1 the whole dossier, A2 §4.3B and the Excel model preset to 1,400,000 members, A3 the two subgroup rows of §3.2B as a 3-page excerpt. A4, adolescents aged 12–17, is not answered from the binder.
A4: “Not answered from the binder: an unapproved use (label §8.4) · Medical Information replies.”
The request letter sits beside the answers, with the unsolicited check: it came in unprompted through the portal, the requester sits on the P&T committee, and there was no company contact in the 30 days before. Priya sends v6.0, since its October 24 sign-off falls before the October 29 packet deadline. The budget impact model, preset to Crestline, shows +$0.031 per member per month in year 1, rising to +$0.087 in year 3, with every input left editable.
Unsolicited check: “No company contact in the 30 days before.”
The packet holds a cover letter that answers A1–A3 one by one and says A4 is answered separately, the v6.0 dossier (released when it is signed), the Crestline budget model and the evidence excerpt. The payer deck stays out, because Crestline did not ask for slides. Priya hands A4 to Dana Okafor in Medical Information, then Omar Haddad and Lena Ortiz approve, and the packet can go through the portal ahead of the October 29 deadline.
“Payer deck left out. Crestline did not ask for slides, so the deck stays with Sam Patel for the account meeting.”
The same dossier and the same payer request, seen by the five people who carry them — what their week looked like, and what it looks like now.
Six specialist agents keep every section current with the evidence and build each payer packet; the dossier owner decides and MLR approves.
Reads each payer request from the portal, email or an account director, splits it into numbered asks quoting the requester, and records why it counts as unsolicited — channel, requester role and any company contact in the 30 days before — with any standing request for updates.
Maps every source to AMCP Format 5.0 sections and, when a source is new or revised, finds each section whose claims depend on it, marks it changed, unchanged after review or not affected, and keeps the change log against the last published edition.
Reads values from tables, forest plots, bar charts and Kaplan–Meier curves with their confidence intervals, page and figure number, and checks each against the text or the source table.
Drafts each changed section in the AMCP Format 5.0 structure with a citation on every value, keeping sentences that are still correct word for word so the redline stays small.
Classifies every claim and every payer ask as consistent with the label, health care economic information related to an approved indication, pre-approval information, or an unapproved use — and cites the label passage behind the call.
Assembles the tailored packet — a cover letter listing what changed since the edition the payer has, the dossier and the plan's preset budget model — and derives payer decks that say only what the signed dossier says, with a section citation on every slide.
Decides; MLR approves. The agents propose; a named person decides.
Ask in plain words about a dossier, a payer request or a source — or tell it what to change. Every answer points to its source.
Which sections are out of date, and why?
3 sections are out of date: §1.1B Clinical benefits, §3.1B Study summaries and §3.2B Evidence tables. Each rests on VLT-302, and the week-100 abstract entered the library after their last update. §6.1B references were updated automatically. One click on the binder drafts all three, then they go to Omar Haddad for review.
Why is the adolescent question going to Medical Information?
Because it is an unapproved use. The label says the safety and effectiveness of Veltrimab in pediatric patients with ulcerative colitis have not been established. Crestline asked about it unprompted, so Medical Information (Dana Okafor) answers it separately, factually and on the record — it never goes in the dossier packet.
What does the budget model show?
For a hypothetical 1,000,000-member plan the UC model shows +$0.031 per member per month in year 1, rising to +$0.087 in year 3 — uptake 4%, 8% and 12% among patients on an advanced therapy. Preset to Crestline's 1.4M members, every input stays editable in the Excel file they receive.
Add a rule: hold any packet that includes material the payer did not ask for
Added and switched on: “Hold any packet that includes material the payer did not ask for.” The packet builder now lists each file against the ask it answers and holds anything that answers none. It already applies to Crestline — the payer deck stays out.
13 screens from the working solution, on its sample data. Pick one to see it large.
Who approves, which rules the agents follow and how packets go out are settings, changed by the people who own them.
| Setting | Default | Choose from |
|---|---|---|
| Medical review | Omar Haddad · every section and packet | Any person on the team |
| Regulatory & legal review | Lena Ortiz · keeps the unsolicited record | Any person on the team |
| Unapproved-use questions | Dana Okafor · answered outside the packet | Any person on the team |
| Check every request is unsolicited before anything is built | On · required | Always on |
| Mark a section out of date the moment a source it rests on is newer | On | On · Off |
| Send an updated dossier only under a standing request | On | On · Off |
| Packet deadline | 14 days before each P&T meeting | Step up or down, one day at a time |
| Budget model format | Excel workbook, inputs unlocked | Excel workbook, inputs unlocked · Web calculator link |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample dossier and request data · “target” = the design goal, measured in the live solution · “estimated” = our estimate · “typical” = published figures (ISPOR 2026, automated AMCP dossier development with a multi-agent approach — about 80% less development time, 70–75% lower cost, a first draft about 90% complete; a single study, not a measured result of this solution). Context: AMCP Format for Formulary Submissions 5.0 (2024); FDA payor communications guidance. People, products, health plans and requests named on this page are fictional — characters and sample data in the working solution.
It is the work of building and keeping current a product's dossier in the AMCP Format for Formulary Submissions, which US payers' P&T committees expect from manufacturers when they ask for it. AMCP Dossier Development keeps the dossier as a binder of AMCP sections, each tied to the sources it rests on, and answers each unsolicited payer request from it.
The evidence mapper knows which label revision, study report, publication, model report or pricing memo each section rests on. When a newer source enters the evidence library, every section that rests on it and was last updated before it is marked out of date, and the section owner is told at once. In the working solution a week-100 abstract marked three sections out of date the moment it was added.
The request intake agent splits each request into the payer's own asks and records why it is unsolicited — channel, requester role and no company contact in the 30 days before. Each ask is matched to the sections that answer it, and the packet holds only what was asked: a cover letter, the dossier edition and, when asked for, the budget impact model preset to the plan's membership.
The label and claims checker classifies the ask against the current prescribing information and cites the label passage. An unapproved use, such as Crestline's question about adolescents with ulcerative colitis, never enters the packet; it is handed to Medical Information, who answer it separately and on the record.
Yes. The packet carries the model as an Excel workbook preset to the plan's membership, with every input left unlocked. Members, prevalence and uptake can be changed in the solution before it is sent, and the per-member-per-month results update.
Only to accounts that asked for updates. Following AMCP Format 5.0, updated dossiers go to earlier requesters only under a standing request, for the period they stated. While a new edition is under revision, the last completed edition can be offered, with a cover letter that says when the new one is expected.
Yes. The agents draft, check and assemble; they never sign, send or answer an unapproved-use question. The dossier owner signs sections and decides each packet, medical review and regulatory and legal review both approve it before it goes out, and every step is on the activity trail.
The Agentic Solution Engine builds and deploys it from your requirements and documents — your dossiers, their evidence, your review rules and a sample of past payer requests — and it goes live once every quality gate has passed. We will walk you through it on one of your own dossiers first.
Every GVD sentence linked to its source and checked against the label.
1-min demoRebate Claims ValidationEvery rebate invoice line checked, every dispute backed by its clause.
1-min demoPayer Contract ManagementEvery payer contract turned into cited terms, every deadline tracked
1-min demoWe'll run AMCP Dossier Development on one of your own dossiers, its evidence and a past payer request.